Neoadjuvant Chemotherapy Therapy Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study
Conditions: Locally Advanced Rectal Cancer; Total Neoadjuvant Treatment; Anti-PD-1 Intervention: Other: nCRT → (CapeOX+Sintilimab)×6 → Surgery/W&W Sponsor: The First Hospital of Jilin University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 18, 2023 Category: Research Source Type: clinical trials
Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma
Conditions: Esophageal Carcinoma; Neoadjuvant Therapy Interventions: Drug: Toripalimab; Drug: Anlotinib hydrochloride; Drug: Albumin paclitaxel; Drug: Cisplatin Sponsor: Nanfang Hospital, Southern Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 18, 2023 Category: Research Source Type: clinical trials
Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study
Conditions: Locally Advanced Rectal Cancer; Total Neoadjuvant Treatment; Anti-PD-1 Intervention: Other: nCRT → (CapeOX+Sintilimab)×6 → Surgery/W&W Sponsor: The First Hospital of Jilin University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 18, 2023 Category: Research Source Type: clinical trials
Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma
Conditions: Esophageal Carcinoma; Neoadjuvant Therapy Interventions: Drug: Toripalimab; Drug: Anlotinib hydrochloride; Drug: Albumin paclitaxel; Drug: Cisplatin Sponsor: Nanfang Hospital, Southern Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 18, 2023 Category: Research Source Type: clinical trials
Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study
Conditions: Locally Advanced Rectal Cancer; Total Neoadjuvant Treatment; Anti-PD-1 Intervention: Other: nCRT → (CapeOX+Sintilimab)×6 → Surgery/W&W Sponsor: The First Hospital of Jilin University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 18, 2023 Category: Research Source Type: clinical trials
Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma
Conditions: Esophageal Carcinoma; Neoadjuvant Therapy Interventions: Drug: Toripalimab; Drug: Anlotinib hydrochloride; Drug: Albumin paclitaxel; Drug: Cisplatin Sponsor: Nanfang Hospital, Southern Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 18, 2023 Category: Research Source Type: clinical trials
Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study
Conditions: Locally Advanced Rectal Cancer; Total Neoadjuvant Treatment; Anti-PD-1 Intervention: Other: nCRT → (CapeOX+Sintilimab)×6 → Surgery/W&W Sponsor: The First Hospital of Jilin University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 18, 2023 Category: Research Source Type: clinical trials
Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma
Conditions: Esophageal Carcinoma; Neoadjuvant Therapy Interventions: Drug: Toripalimab; Drug: Anlotinib hydrochloride; Drug: Albumin paclitaxel; Drug: Cisplatin Sponsor: Nanfang Hospital, Southern Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 17, 2023 Category: Research Source Type: clinical trials
Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study
Conditions: Locally Advanced Rectal Cancer; Total Neoadjuvant Treatment; Anti-PD-1 Intervention: Other: nCRT → (CapeOX+Sintilimab)×6 → Surgery/W&W Sponsor: The First Hospital of Jilin University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 17, 2023 Category: Research Source Type: clinical trials
Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma
Conditions: Esophageal Carcinoma; Neoadjuvant Therapy Interventions: Drug: Toripalimab; Drug: Anlotinib hydrochloride; Drug: Albumin paclitaxel; Drug: Cisplatin Sponsor: Nanfang Hospital, Southern Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 17, 2023 Category: Research Source Type: clinical trials
Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study
Conditions: Locally Advanced Rectal Cancer; Total Neoadjuvant Treatment; Anti-PD-1 Intervention: Other: nCRT → (CapeOX+Sintilimab)×6 → Surgery/W&W Sponsor: The First Hospital of Jilin University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 17, 2023 Category: Research Source Type: clinical trials
